RA Capital Management’s Prevail Therapeutics PRVL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
– Sell
-1,915,568
Closed -$19.5M – 91
2020
Q3
$19.5M Sell
1,915,568
-579,123
-23% -$7.77M 0.36% 50
2020
Q2
$37.2M Sell
2,494,691
-745,843
-23% -$11.5M 0.72% 34
2020
Q1
$39.5M Sell
3,240,534
-123,071
-4% -$1.96M 1.25% 26
2019
Q4
$53.2M Hold
3,363,605
– – 1.61% 18
2019
Q3
$41.3M Buy
3,363,605
+619,980
+23% +$7.03M 2.46% 12
2019
Q2
$36.2M Buy
+2,743,625
New +$40M 1.94% 14

Other funds holding PRVL

RA Capital Management's PRVL Position: Q4 2020 in Review

RA Capital Management sold out of Prevail Therapeutics (PRVL) in Q4 2020, closing a stake of 1,915,568 shares — an estimated $19.5M sold.

RA Capital Management first reported a position in PRVL in Q2 2019 and held it in 6 quarters. The position peaked at $53.2M in Q4 2019. 93 funds tracked by Wall St. Rank hold PRVL as of Q4 2020.

  • RA Capital Management reported no remaining Prevail Therapeutics position as of Q4 2020 after selling out during the quarter.
  • RA Capital Management sold 1,915,568 Prevail Therapeutics shares in Q4 2020, an estimated $19.5M.
  • RA Capital Management first reported a position in Prevail Therapeutics in Q2 2019 and held it in 6 quarters.
  • RA Capital Management's Prevail Therapeutics position peaked at $53.2M in Q4 2019.
  • 93 funds tracked by Wall St. Rank held Prevail Therapeutics as of Q4 2020.

Based on RA Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.